The ILDsym™ QSP modeling software is a mechanistic, mathematical model of interstitial lung disease (ILD) associated with systemic sclerosis (SSc).
ILDsym can be used to predict efficacy for treatment modalities developed for SSc-ILD (and other interstitial lung diseases with custom modifications and additions).
ILDsym has been utilized to:
- Evaluate compounds in drug development
- Suppor clinical trial design optimization
- Clinical development decision-making
Speakers: Lisl Shoda, Associate Vice President and Director of Immunology and Zack Kenz, Sr. Scientist for an insightful presentation and informative Q& A session hosted by Scott Q. Siler, Chief Scientific Officer.